DDrare: Database of Drug Development for Rare Diseases

Searched query = "Huge venous malformation with cervical, oral and pharyngeal diffuse lesion", "Huge venous malformation", "Venous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Alcohol; Bleomycin; Bleomycin + Fibrovein; Bleomycin Baxter; Dehydrated Alcohol (Absolute Alcohol) BP for Injection; ETHANOL (96 PER CENT); ETHANOL BP; Ethanol; Ethanol 96% Gel; Ethanol 98% Solution; Ethanol gel; Ethanolamine; Ethanolamine oleate; Fibrovein; Fibrovein 3%; Iopamiron; L0122; Polidocanol; Rapamycin; Sirolimus; Trametinib; Trametinib tablet; VT30

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-001455-37-NO (EUCTR)	21/12/2011	01/06/2011	Prospective randomized interventional study in patients with venous malformations.	Prospective randomized interventional study. Compare the effect of bleomycin and Tetradecyl Sodium Sulphate (Fibrovein) in the treatment of venous malformations. Clinical neurological and neurophysiological study of a subpopulation of patients with venous malformations.	Venous malformation MedDRA version: 13.1;Level: LLT;Classification code 10047229;Term: Venous malformation NOS;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Bleomycin Baxter Product Name: Bleomycin Trade Name: Fibrovein 3% Product Name: Fibrovein 3%	Department of Radiology, Oslo University Hospital, Norway	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Norway
2	NCT01347294 (ClinicalTrials.gov)	August 2011	11/4/2011	Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations	Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations	Venous Malformation	Drug: Bleomycin;Drug: Fibrovein;Drug: Bleomycin + Fibrovein	Oslo University Hospital	NULL	Recruiting	12 Years	80 Years	All	126	Phase 4	Norway

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-001455-37-NO
(EUCTR)

21/12/2011

01/06/2011

Prospective randomized interventional study in patients with venous malformations.

Prospective randomized interventional study. Compare the effect of bleomycin and Tetradecyl Sodium Sulphate (Fibrovein) in the treatment of venous malformations. Clinical neurological and neurophysiological study of a subpopulation of patients with venous malformations.

Venous malformation
MedDRA version: 13.1;Level: LLT;Classification code 10047229;Term: Venous malformation NOS;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Trade Name: Bleomycin Baxter
Product Name: Bleomycin
Trade Name: Fibrovein 3%
Product Name: Fibrovein 3%

Department of Radiology, Oslo University Hospital, Norway

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Norway

NCT01347294
(ClinicalTrials.gov)

August 2011

11/4/2011

Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations

Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations

Venous Malformation

Drug: Bleomycin;Drug: Fibrovein;Drug: Bleomycin + Fibrovein

Oslo University Hospital

NULL

Recruiting

12 Years

80 Years

All

126

Phase 4

Norway